Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with M

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
4344 Q3 2021 MAGNESIUM OXIDE BUCCAL GUM, CHEWING 7.20 mg MDE Replacement
4344 Q4 2021 MAGNESIUM OXIDE BUCCAL GUM, CHEWING 144 mg MDE Replacement
4386 Q3 2021 MAGNESIUM STEARATE ORAL TABLET, CHEWABLE, EXTENDED RELEASE 6.00 mg MDE Replacement
4386 Q4 2021 MAGNESIUM STEARATE ORAL TABLET, CHEWABLE, EXTENDED RELEASE 9 mg MDE Replacement
4390 Q3 2021 MAGNESIUM STEARATE ORAL TABLET, EXTENDED RELEASE 150.00 mg MDE Replacement
4390 Q4 2021 MAGNESIUM STEARATE ORAL TABLET, EXTENDED RELEASE 160 mg MDE Replacement
4452 Q3 2021 MALTODEXTRIN ORAL SOLUTION 145.10 mg MDE Replacement
4452 Q4 2021 MALTODEXTRIN ORAL SOLUTION 1451 mg MDE Replacement
4476 Q3 2021 MANNITOL INTRAVENOUS INJECTION 1000.00 mg MDE Replacement
4476 Q4 2021 MANNITOL INTRAVENOUS INJECTION 15200 mg MDE Replacement
4495 Q3 2021 MANNITOL ORAL CAPSULE, EXTENDED RELEASE 53.40 mg MDE Replacement
4495 Q4 2021 MANNITOL ORAL CAPSULE, EXTENDED RELEASE 160.2 mg MDE Replacement
4500 Q3 2021 MANNITOL ORAL POWDER, FOR SOLUTION 1345.50 mg MDE Replacement
4500 Q4 2021 MANNITOL ORAL POWDER, FOR SOLUTION 3767.4 mg MDE Replacement
4507 Q3 2021 MANNITOL ORAL TABLET, CHEWABLE, EXTENDED RELEASE 410.60 mg MDE Replacement
4507 Q4 2021 MANNITOL ORAL TABLET, CHEWABLE, EXTENDED RELEASE 615.9 mg MDE Replacement
4510 Q3 2021 MANNITOL ORAL TABLET, EXTENDED RELEASE 392.20 mg MDE Replacement
4510 Q4 2021 MANNITOL ORAL TABLET, EXTENDED RELEASE 434 mg MDE Replacement
4548 Q3 2021 MEDIUM-CHAIN TRIGLYCERIDES SUBLINGUAL POWDER 0.80 mg MDE Replacement
4548 Q4 2021 MEDIUM-CHAIN TRIGLYCERIDES SUBLINGUAL POWDER 2.4 mg MDE Replacement
4551 Q3 2021 MEDIUM-CHAIN TRIGLYCERIDES TOPICAL CREAM 15.00 %w/w MDE Replacement
4551 Q4 2021 MEDIUM-CHAIN TRIGLYCERIDES TOPICAL CREAM 570 mg MDE Replacement
4611 Q3 2021 METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A ORAL GRANULE, FOR SUSPENSION 38.00 mg MDE Replacement
4611 Q4 2021 METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A ORAL GRANULE, FOR SUSPENSION 82.2 mg MDE Replacement
4647 Q3 2021 METHACRYLIC ACID COPOLYMER ORAL TABLET, EXTENDED RELEASE 61.91 mg MDE Replacement
4647 Q4 2021 METHACRYLIC ACID COPOLYMER ORAL TABLET, EXTENDED RELEASE 99.3 mg MDE Replacement
4697 Q3 2021 METHYLCELLULOSE ORAL TABLET 183.60 mg MDE Replacement
4697 Q4 2021 METHYLCELLULOSE ORAL TABLET 816 mg MDE Replacement
4716 Q3 2021 METHYLCELLULOSE (1500 MPA.S) ORAL TABLET 2.75 mg MDE Replacement
4716 Q4 2021 METHYLCELLULOSE (1500 MPA.S) ORAL TABLET 319.2 mg MDE Replacement
4725 Q3 2021 METHYLPARABEN BUCCAL FILM 1.00 mg MDE Replacement
4725 Q4 2021 METHYLPARABEN BUCCAL FILM 1 mg MDE Replacement
4726 Q3 2021 METHYLPARABEN BUCCAL FILM, SOLUBLE 0.71 mg MDE Replacement
4726 Q4 2021 METHYLPARABEN BUCCAL FILM, SOLUBLE 3 mg MDE Replacement
4802 Q3 2021 METHYLPARABEN VAGINAL CREAM 0.20 %w/w MDE Replacement
4802 Q4 2021 METHYLPARABEN VAGINAL CREAM 6 mg MDE Replacement
4832 Q3 2021 MICROCRYSTALLINE CELLULOSE ORAL TABLET, CHEWABLE, EXTENDED RELEASE 96.00 mg MDE Replacement
4832 Q4 2021 MICROCRYSTALLINE CELLULOSE ORAL TABLET, CHEWABLE, EXTENDED RELEASE 144 mg MDE Replacement
4868 Q3 2021 MINERAL OIL TOPICAL CREAM 50.62 %w/w MDE Replacement
4868 Q4 2021 MINERAL OIL TOPICAL CREAM 1518 mg MDE Replacement
4904 Q3 2021 MONOBASIC POTASSIUM PHOSPHATE INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 68.00 mg MDE Replacement
4904 Q4 2021 MONOBASIC POTASSIUM PHOSPHATE INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 110.16 mg MDE Replacement
4360 Q4 2021 MAGNESIUM STEARATE BUCCAL TABLET, DELAYED RELEASE 0.58 mg 1 mg Deletion
4710 Q4 2021 METHYLCELLULOSE VAGINAL TABLET 102.00 mg Deletion
4814 Q4 2021 MICROCRYSTALLINE CELLULOSE BUCCAL TABLET, DELAYED RELEASE 18.04 mg Deletion
4853 Q4 2021 MILK PROTEIN CONCENTRATE BUCCAL TABLET, DELAYED RELEASE 23.00 mg 23 mg Deletion

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: September 30, 2021
Database Last Updated: October 21, 2021

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English